메뉴 건너뛰기




Volumn 23, Issue 22, 2017, Pages 6812-6822

Expression of PD-L1 in hormone-naïve and treated prostate cancer patients receiving neoadjuvant abiraterone acetate plus prednisone and leuprolide

Author keywords

[No Author keywords available]

Indexed keywords

ABIRATERONE ACETATE; LEUPRORELIN; PREDNISONE; PROGRAMMED DEATH 1 LIGAND 1; PROSTATE SPECIFIC ANTIGEN; PROTEIN MSH2; ANTINEOPLASTIC AGENT; CD274 PROTEIN, HUMAN;

EID: 85034863535     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-17-0807     Document Type: Article
Times cited : (78)

References (36)
  • 2
    • 84958033425 scopus 로고    scopus 로고
    • The 2014 International Society of Urological Pathology (ISUP) consensus conference on gleason grading of prostatic carcinoma: Definition of grading patterns and proposal for a new grading system
    • Epstein JI, Egevad L, Amin MB, Delahunt B, Srigley JR, Humphrey PA. The 2014 International Society of Urological Pathology (ISUP) consensus conference on gleason grading of prostatic carcinoma: definition of grading patterns and proposal for a new grading system. Am J Surg Pathol 2016; 40:244–52.
    • (2016) Am J Surg Pathol , vol.40 , pp. 244-252
    • Epstein, J.I.1    Egevad, L.2    Amin, M.B.3    Delahunt, B.4    Srigley, J.R.5    Humphrey, P.A.6
  • 3
    • 58549118240 scopus 로고    scopus 로고
    • A systematic review and meta-analysis of randomised trials of neo-adjuvant hormone therapy for localised and locally advanced prostate carcinoma
    • Shelley MD, Kumar S, Wilt T, Staffurth J, Coles B, Mason MD. A systematic review and meta-analysis of randomised trials of neo-adjuvant hormone therapy for localised and locally advanced prostate carcinoma. Cancer Treat Rev 2009;35:9–17.
    • (2009) Cancer Treat Rev , vol.35 , pp. 9-17
    • Shelley, M.D.1    Kumar, S.2    Wilt, T.3    Staffurth, J.4    Coles, B.5    Mason, M.D.6
  • 4
    • 84905993578 scopus 로고    scopus 로고
    • Intense androgen-deprivation therapy with abiraterone acetate plus leuprolide acetate in patients with localized high-risk prostate cancer: Results of a randomized phase II neoadjuvant study
    • Taplin ME, Montgomery B, Logothetis CJ, Bubley GJ, Richie JP, Dalkin BL, et al. Intense androgen-deprivation therapy with abiraterone acetate plus leuprolide acetate in patients with localized high-risk prostate cancer: results of a randomized phase II neoadjuvant study. J Clin Oncol 2014;32: 3705–15.
    • (2014) J Clin Oncol , vol.32 , pp. 3705-3715
    • Taplin, M.E.1    Montgomery, B.2    Logothetis, C.J.3    Bubley, G.J.4    Richie, J.P.5    Dalkin, B.L.6
  • 5
    • 84938350452 scopus 로고    scopus 로고
    • Combination cancer immunotherapy and new immunomodulatory targets
    • Mahoney KM, Rennert PD, Freeman GJ. Combination cancer immunotherapy and new immunomodulatory targets. Nat Rev Drug Discov 2015; 14:561–84.
    • (2015) Nat Rev Drug Discov , vol.14 , pp. 561-584
    • Mahoney, K.M.1    Rennert, P.D.2    Freeman, G.J.3
  • 6
    • 84937516588 scopus 로고    scopus 로고
    • A systematic review of immunotherapy in urologic cancer: Evolving roles for targeting of CTLA-4, PD-1/PD-L1, and HLA-G
    • Carosella ED, Ploussard G, LeMaoult J, Desgrandchamps F. A systematic review of immunotherapy in urologic cancer: evolving roles for targeting of CTLA-4, PD-1/PD-L1, and HLA-G. Eur Urol 2015;68:267–79.
    • (2015) Eur Urol , vol.68 , pp. 267-279
    • Carosella, E.D.1    Ploussard, G.2    LeMaoult, J.3    Desgrandchamps, F.4
  • 8
    • 84939227614 scopus 로고    scopus 로고
    • Differential activity of nivolumab, pembrolizumab and MPDL3280A according to the tumor expression of programmed death-ligand-1 (PD-L1): Sensitivity analysis of trials in melanoma, lung and genitourinary cancers
    • Carbognin L, Pilotto S, Milella M, Vaccaro V, Brunelli M, Calio A, et al. Differential activity of nivolumab, pembrolizumab and MPDL3280A according to the tumor expression of programmed death-ligand-1 (PD-L1): sensitivity analysis of trials in melanoma, lung and genitourinary cancers. PLoS One 2015;10:e0130142.
    • (2015) PLoS One , vol.10
    • Carbognin, L.1    Pilotto, S.2    Milella, M.3    Vaccaro, V.4    Brunelli, M.5    Calio, A.6
  • 9
    • 84904024273 scopus 로고    scopus 로고
    • Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy
    • Taube JM, Klein A, Brahmer JR, Xu H, Pan X, Kim JH, et al. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin Cancer Res 2014;20: 5064–74.
    • (2014) Clin Cancer Res , vol.20 , pp. 5064-5074
    • Taube, J.M.1    Klein, A.2    Brahmer, J.R.3    Xu, H.4    Pan, X.5    Kim, J.H.6
  • 11
    • 84946935007 scopus 로고    scopus 로고
    • Magnitude of PD-1, PD-L1 and T lymphocyte expression on tissue from castration-resistant prostate adenocarcinoma: An exploratory analysis
    • Massari F, Ciccarese C, Calio A, Munari E, Cima L, Porcaro AB, et al. Magnitude of PD-1, PD-L1 and T lymphocyte expression on tissue from castration-resistant prostate adenocarcinoma: an exploratory analysis. Target Oncol 2016;11:345–51.
    • (2016) Target Oncol , vol.11 , pp. 345-351
    • Massari, F.1    Ciccarese, C.2    Calio, A.3    Munari, E.4    Cima, L.5    Porcaro, A.B.6
  • 12
    • 84967166401 scopus 로고    scopus 로고
    • The immune checkpoint regulator PD-L1 is highly expressed in aggressive primary prostate cancer
    • Gevensleben H, Dietrich D, Golletz C, Steiner S, Jung M, Thiesler T, et al. The immune checkpoint regulator PD-L1 is highly expressed in aggressive primary prostate cancer. Clin Cancer Res 2016;22:1969–77.
    • (2016) Clin Cancer Res , vol.22 , pp. 1969-1977
    • Gevensleben, H.1    Dietrich, D.2    Golletz, C.3    Steiner, S.4    Jung, M.5    Thiesler, T.6
  • 13
    • 85017503544 scopus 로고    scopus 로고
    • The prognostic role of immune checkpoint markers programmed cell death protein 1 (PD-1) and programmed death ligand 1 (PD-L1) in a large, multicenter prostate cancer cohort
    • Ness N, Andersen S, Khanehkenari MR, Nordbakken CV, Valkov A, Paulsen EE, et al. The prognostic role of immune checkpoint markers programmed cell death protein 1 (PD-1) and programmed death ligand 1 (PD-L1) in a large, multicenter prostate cancer cohort. Oncotarget 2017;8:26789–801.
    • (2017) Oncotarget , vol.8 , pp. 26789-26801
    • Ness, N.1    Andersen, S.2    Khanehkenari, M.R.3    Nordbakken, C.V.4    Valkov, A.5    Paulsen, E.E.6
  • 14
    • 84960080350 scopus 로고    scopus 로고
    • Comparative study of the PD-L1 status between surgically resected specimens and matched biopsies of NSCLC patients reveal major discor-dances: A potential issue for anti-PD-L1 therapeutic strategies
    • Ilie M, Long-Mira E, Bence C, Butori C, Lassalle S, Bouhlel L, et al. Comparative study of the PD-L1 status between surgically resected specimens and matched biopsies of NSCLC patients reveal major discor-dances: a potential issue for anti-PD-L1 therapeutic strategies. Ann Oncol 2016;27:147–53.
    • (2016) Ann Oncol , vol.27 , pp. 147-153
    • Ilie, M.1    Long-Mira, E.2    Bence, C.3    Butori, C.4    Lassalle, S.5    Bouhlel, L.6
  • 15
    • 84959577118 scopus 로고    scopus 로고
    • Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: A single-arm, multicentre, phase 2 trial
    • Rosenberg JE, Hoffman-Censits J, Powles T, van der Heijden MS, Balar AV, Necchi A, et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet 2016;387:1909–20.
    • (2016) Lancet , vol.387 , pp. 1909-1920
    • Rosenberg, J.E.1    Hoffman-Censits, J.2    Powles, T.3    Van Der Heijden, M.S.4    Balar, A.V.5    Necchi, A.6
  • 16
    • 84923078390 scopus 로고    scopus 로고
    • MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer
    • Powles T, Eder JP, Fine GD, Braiteh FS, Loriot Y, Cruz C, et al. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature 2014;515:558–62.
    • (2014) Nature , vol.515 , pp. 558-562
    • Powles, T.1    Eder, J.P.2    Fine, G.D.3    Braiteh, F.S.4    Loriot, Y.5    Cruz, C.6
  • 17
    • 84920956735 scopus 로고    scopus 로고
    • Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
    • Herbst RS, Soria JC, Kowanetz M, Fine GD, Hamid O, Gordon MS, et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 2014;515:563–7.
    • (2014) Nature , vol.515 , pp. 563-567
    • Herbst, R.S.1    Soria, J.C.2    Kowanetz, M.3    Fine, G.D.4    Hamid, O.5    Gordon, M.S.6
  • 20
    • 84964858970 scopus 로고    scopus 로고
    • Assessment of the PD-L1 status by immunohistochemistry: Challenges and perspectives for therapeutic strategies in lung cancer patients
    • Ilie M, Hofman V, Dietel M, Soria JC, Hofman P. Assessment of the PD-L1 status by immunohistochemistry: challenges and perspectives for therapeutic strategies in lung cancer patients. Virchows Arch 2016;468: 511–25.
    • (2016) Virchows Arch , vol.468 , pp. 511-525
    • Ilie, M.1    Hofman, V.2    Dietel, M.3    Soria, J.C.4    Hofman, P.5
  • 23
    • 85020475365 scopus 로고    scopus 로고
    • The PD-1 expressing immune phenotype of T cell exhaustion is prominent in the `immunoreactive' microenvironment of colorectal carcinoma
    • Prall F, Huhns M. The PD-1 expressing immune phenotype of T cell exhaustion is prominent in the `immunoreactive' microenvironment of colorectal carcinoma. Histopathology 2017;71:366–74.
    • (2017) Histopathology , vol.71 , pp. 366-374
    • Prall, F.1    Huhns, M.2
  • 24
    • 84938984463 scopus 로고    scopus 로고
    • The prognostic landscape of genes and infiltrating immune cells across human cancers
    • Gentles AJ, Newman AM, Liu CL, Bratman SV, Feng W, Kim D, et al. The prognostic landscape of genes and infiltrating immune cells across human cancers. Nat Med 2015;21:938–45.
    • (2015) Nat Med , vol.21 , pp. 938-945
    • Gentles, A.J.1    Newman, A.M.2    Liu, C.L.3    Bratman, S.V.4    Feng, W.5    Kim, D.6
  • 25
    • 20244380618 scopus 로고    scopus 로고
    • Androgen ablation mitigates tolerance to a prostate/prostate cancer-restricted antigen
    • Drake CG, Doody AD, Mihalyo MA, Huang CT, Kelleher E, Ravi S, et al. Androgen ablation mitigates tolerance to a prostate/prostate cancer-restricted antigen. Cancer Cell 2005;7:239–49.
    • (2005) Cancer Cell , vol.7 , pp. 239-249
    • Drake, C.G.1    Doody, A.D.2    Mihalyo, M.A.3    Huang, C.T.4    Kelleher, E.5    Ravi, S.6
  • 26
    • 77951937514 scopus 로고    scopus 로고
    • Prostate cancer patients on androgen deprivation therapy develop persistent changes in adaptive immune responses
    • Morse MD, McNeel DG. Prostate cancer patients on androgen deprivation therapy develop persistent changes in adaptive immune responses. Hum Immunol 2010;71:496–504.
    • (2010) Hum Immunol , vol.71 , pp. 496-504
    • Morse, M.D.1    McNeel, D.G.2
  • 28
    • 33947399305 scopus 로고    scopus 로고
    • Neonatal castration affects intrathymic kinetics of T-cell differentiation and the spleen T-cell level
    • Radojevic K, Arsenovic-Ranin N, Kosec D, Pesic V, Pilipovic I, Perisic M, et al. Neonatal castration affects intrathymic kinetics of T-cell differentiation and the spleen T-cell level. J Endocrinol 2007;192:669–82.
    • (2007) J Endocrinol , vol.192 , pp. 669-682
    • Radojevic, K.1    Arsenovic-Ranin, N.2    Kosec, D.3    Pesic, V.4    Pilipovic, I.5    Perisic, M.6
  • 29
    • 68749087029 scopus 로고    scopus 로고
    • Characterization of the intra-prostatic immune cell infiltration in androgen-deprived prostate cancer patients
    • Gannon PO, Poisson AO, Delvoye N, Lapointe R, Mes-Masson AM, Saad F. Characterization of the intra-prostatic immune cell infiltration in androgen-deprived prostate cancer patients. J Immunol Methods 2009; 348:9–17.
    • (2009) J Immunol Methods , vol.348 , pp. 9-17
    • Gannon, P.O.1    Poisson, A.O.2    Delvoye, N.3    Lapointe, R.4    Mes-Masson, A.M.5    Saad, F.6
  • 30
    • 84860133344 scopus 로고    scopus 로고
    • Increased CD8+ T-cell function following castration and immunization is countered by parallel expansion of regulatory T cells
    • Tang S, Moore ML, Grayson JM, Dubey P. Increased CD8+ T-cell function following castration and immunization is countered by parallel expansion of regulatory T cells. Cancer Res 2012;72:1975–85.
    • (2012) Cancer Res , vol.72 , pp. 1975-1985
    • Tang, S.1    Moore, M.L.2    Grayson, J.M.3    Dubey, P.4
  • 31
    • 84963589359 scopus 로고    scopus 로고
    • Androgen receptor antagonists compromise T cell response against prostate cancer leading to early tumor relapse
    • Pu Y, Xu M, Liang Y, Yang K, Guo Y, Yang X, et al. Androgen receptor antagonists compromise T cell response against prostate cancer leading to early tumor relapse. Sci Transl Med 2016;8:333ra47.
    • (2016) Sci Transl Med , vol.8 , pp. 333ra47
    • Pu, Y.1    Xu, M.2    Liang, Y.3    Yang, K.4    Guo, Y.5    Yang, X.6
  • 32
    • 84946195510 scopus 로고    scopus 로고
    • The molecular taxonomy of primary prostate cancer
    • Cancer Genome Atlas Research Network
    • Cancer Genome Atlas Research Network.The molecular taxonomy of primary prostate cancer. Cell 2015;163:1011–25.
    • (2015) Cell , vol.163 , pp. 1011-1025
  • 33
    • 84978786133 scopus 로고    scopus 로고
    • Programmed cell death ligand-1 (PD-L1) expression by immunohistochemistry: Could it be predictive and/or prognostic in non-small cell lung cancer?
    • Mino-Kenudson M.Programmed cell death ligand-1 (PD-L1) expression by immunohistochemistry: could it be predictive and/or prognostic in non-small cell lung cancer? Cancer Biol Med 2016;13:157–70.
    • (2016) Cancer Biol Med , vol.13 , pp. 157-170
    • Mino-Kenudson, M.1
  • 34
    • 33846118474 scopus 로고    scopus 로고
    • Loss of tumor suppressor PTEN function increases B7-H1 expression and immu-noresistance in glioma
    • Parsa AT, Waldron JS, Panner A, Crane CA, Parney IF, Barry JJ, et al. Loss of tumor suppressor PTEN function increases B7-H1 expression and immu-noresistance in glioma. Nat Med 2007;13:84–8.
    • (2007) Nat Med , vol.13 , pp. 84-88
    • Parsa, A.T.1    Waldron, J.S.2    Panner, A.3    Crane, C.A.4    Parney, I.F.5    Barry, J.J.6
  • 35
    • 84969185739 scopus 로고    scopus 로고
    • Do African-American men need separate prostate cancer screening guidelines?
    • Shenoy D, Packianathan S, Chen AM, Vijayakumar S. Do African-American men need separate prostate cancer screening guidelines? BMC Urol 2016;16:19.
    • (2016) BMC Urol , vol.16 , pp. 19
    • Shenoy, D.1    Packianathan, S.2    Chen, A.M.3    Vijayakumar, S.4


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.